US EditionFormosa Pharma and Apotex Ink Deal to Launch Post-Surgery Eye Treatment in Mexico
- Formosa Pharmaceuticals and Apotex Inc. Announced on May 6, 2025, in Taipei an exclusive licensing agreement for Mexico to commercialize APP13007, a post-surgery eye treatment.
- This agreement follows the partnership launched in 2024 and extends Apotex's rights to the Mexican market, pending regulatory approval of APP13007.
- APP13007 is a patented clobetasol propionate ophthalmic suspension 0.05% proven in Phase 3 trials to relieve inflammation and pain after ocular surgery with a convenient dosing regimen.
- Erick Co, CEO of Formosa, stated they are pleased to expand the partnership, while Apotex President Alok Kanti highlighted their confidence APP13007 will reach Mexican patients swiftly.
- The agreement advances Apotex's expansion plans and strengthens its reputation as a preferred collaborator throughout the Americas for acquiring and licensing pharmaceutical products.
88 Articles
88 Articles
The Conway Daily Sun
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension,…
Apotex announces expansion of licensing agreement with Formosa Pharmaceuticals to Mexico for commercialization of clobetasol propionate ophthalmic suspension for the treatment of inflammation and pain following ocular surgery
MEXICO CITY, May 6, 2025 /PRNewswire/ - Apotex Inc. (referred to as "Apotex" or "the Company") today announced it has entered into an exclusive licensing agreement with Formosa Pharmaceuticals ("Formosa", 6838.TW), for exclusive rights in Mexico for the commercialization of…
Formosa Pharma and Apotex Ink Deal to Launch Post-Surgery Eye Treatment in Mexico
TAIPEI, May 7, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights in Mexico for the commercialization of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), a patented innovative medicine for the treatment of inflammation and pain following ocular surgery. Clobetasol propionat…
Coverage Details
Bias Distribution
- 79% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
